In the Liraglutide Effect and Action in Diabetes trial (LEAD-3), GLP-1RA liraglutide treatment significantly reduced body fat, but there was no significant change in lean body mass
Time to deproteinization influences some measures of GSH with additional differences between deproteinized heparinized and EDTA-treated plasma Noting the short half-life of free GSH within plasma and the possibility that heparin and EDTA differentially stabilize REDOX processes of GSH, we examined the impact of time to deproteinization and its interaction with type of anticoagulant used during sample collection on the measured levels of total GSH, free GSH, GSSG, or the ratio of free GSH to GSSG within plasma
Common Drugs Monitored by TDM Aminoglycosides (Gentamicin, Amikacin) Vancomycin Digoxin Lithium Phenytoin Carbamazepine Valproic Acid Tacrolimus Cyclosporine Theophylline Methotrexate Steps in Therapeutic Drug Monitoring Select the patient and drug requiring monitoring
These effects have been tested in humans as well
Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets